GC Genome, a liquid biopsy and clinical genomics specialist, is showing strength in early trading on its first day on the KOSDAQ market.
As of 9:04 a.m. on this day, GC Genome is being traded at 14,600 won, an increase of 4,100 won (39.05%) compared to the offering price of 10,500 won.
GC Genome recorded a competition rate of 547.47 to 1 in the demand forecast for institutional investors conducted from the 19th to the 23rd of last month. A total of 1,692 domestic and foreign institutions participated, and the offering price was confirmed at the upper limit of the desired range (9,000 won to 10,500 won) at 10,500 won.
In the public offering subscription for individual investors held over two days on the 29th and 30th of last month, a competition ratio of 484.1 to 1 was observed. Approximately 2.5415 trillion won was collected as subscription deposits.
GC Genome plans to utilize the funds secured through this listing for research and development aimed at expanding cancer types and cancer pre-cycles.
GC Genome CEO Ki Chang-seok said, “We will strengthen our performance and presence in the global market and aim to become a leading global top-tier liquid biopsy and clinical genomics analysis corporation.”